Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Weight Loss Drugs

Weight Management Hormones Obesity Side Effects Obesity Epidemic Investment Strategies Patient Care Drug Development Pharmaceutical Stocks Drug Efficacy

Novo Nordisk Ends Deal With Hims & Hers Over Compounded Wegovy Copycats

Novo Nordisk cited findings that Hims & Hers continued to sell unapproved Wegovy knock-offs after FDA-declared shortages lifted.

Robinhood Excluded From June S&P 500 Rebalance Despite Doubling in Value

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock